知镜 Cognispect · 医学文献与研究工作台

Effect of a mHealth intervention on detectable HIV-1 viral load: a remote randomised controlled trial.

Carrico AW, Larson ME, Davis-Ewart L, Ghanooni D, Miller-Perusse M, Ackley D, Atkins L, Diaz JE, Balise R, McCollister KE, Fardone E, Neilands TB, Moskowitz JT, Kantor R, Sam SS, Spinelli MA, Hirshfield S, Horvath KJ.
EClinicalMedicine · 2026-11-06 · PMID 43032298

文献摘要

Background Mobile health (mHealth) applications are needed for key populations of people with HIV who experience persistent difficulties with achieving and maintaining undetectable viral load (VL). Methods This remote randomised controlled trial (RCT) tested the efficacy of Supporting Treatment Adherence for Resilience and Thriving (START)-an mHealth application integrating self-monitoring of anti-retroviral therapy (ART) adherence with positive psychological skills (www.clinicaltrials.gov identifier NCT05140876). From 2022 to 2024, 286 sexual minority men with HIV residing in the continental United States who reported recent ART non-adherence and screened positive for a stimulant use disorder (i.e., 92% methamphetamine use disorder) were randomised (1:1) to START (n = 143) or a website control with referrals (n = 143). The primary outcome was detectable VL (>300 copies/mL) at six months (76% retention), measured via remote blood samples. Findings Participants randomised to START had 58% lower odds of detectable VL at six months (adjusted odds ratio [AOR] = 0.42; 95% confidence interval [CI]: 0.19-0.93; p = 0.032). Among the 155 participants with undetectable VL at enrolment (54%), virologic rebound at six months was nearly two-fold greater in the website control versus START (48% versus 25%; p = 0.019). The number needed to treat was 4.75 (95% CI: 2.52-42.00) to prevent one instance of detectable VL. START effects on these VL outcomes were not maintained at 12 months. Interpretation A scalable, mHealth application significantly reduced odds of detectable VL in the short-term, primarily by preventing virologic rebound. Funding National Institute on Drug Abuse (R01-DA049843; UH3-DA058304).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。